Surgery Partners (NASDAQ:SGRY) shares are trading down sharply in Wednesday's session, giving back a large portion of their recent rally as multiple bullish analyst pieces circulated following the company's closing of an approximately $800 million divestiture of its Idaho Falls and Mountain View hospitalAssetsearlier …
Summit Therapeutics (NASDAQ:SMMT) shares are pulling back sharply in Wednesday's session, giving back part of the rally sparked by updated ivonescimab survival data from the HARMONi and Harmoni-6 datasets in lung and biliary tract cancers. That data had fueled speculation about the drug's potential …
Vor Biopharma (NASDAQ:VOR) shares tumbled in Wednesday's session as the company presented its lead pipeline candidate telitacicept at a major virtual immunology and inflammation investor forum, with investors reassessing the drug's dual-indication development path and broader biotech risk profile following the presentation. The sharp …
Vistagen (NASDAQ:VTGN) shares are surging after the company reported preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. In an analysis of 322 subjects who continued into …
Eli Lilly (NYSE:LLY) shares are pulling back roughly 1% in Wednesday's session even as the underlying news flow around the company remains largely positive. CEO Dave Ricks said Lilly is capturing about 70% of new Medicare patients starting weight-loss drugs, a figure that points …
Merck (NYSE:MRK) shares are pulling back in Wednesday's session after a research firm downgraded the stock, arguing shares look overvalued and overbought following a strong rally dating back to mid-2025. The firm pointed to a trailing price-to-earnings ratio above 120 despite only mid-single-digitRevenuegrowth as …
Novo Nordisk (NYSE:NVO) shares are falling further in Wednesday's session as investors continue to digest the company's underwhelming 2030 strategy update from earlier this week. The stock remains under pressure following management's pipeline sales guidance of DKK150 billion by 2035 andRevenuegrowth targets in line …
Parabilis Medicines (NASDAQ:PBLS) shares are sliding further in Wednesday's session, extending a multi-day decline after last week's steep post-earnings selloff triggered by a much wider-than-expected quarterly loss of $2.32 per share against a consensus estimate of $0.16, on minimal revenue of $0.15 million. The …
Rapport Therapeutics (NASDAQ:RAPP) shares are sinking in Wednesday's session as investors book profits ahead of the closely watched Phase 2 bipolar mania readout for lead candidate RAP-219, despite a wave of bullish analyst commentary released the same day. One research firm reiterated a positive …
Inhibrx Biosciences (NASDAQ:INBX) shares are pulling back sharply in Wednesday's session, giving back a portion of the massive gains accumulated since April 2026, when reports first surfaced that Merck (NYSE:MRK) and Ono Pharmaceutical were exploring deals for the company's INBX-106 cancer program, potentially valued …